Хронический гастрит с кишечной эпителий
” “. , , (, , ), . , : ” – , , , …” ” – “. , – “” (, . .), ” “. , , , , . “” ” “, Helicobacter pylori (H. pylori), . , , : , (. 1).
. 1., , . (), . [3]. . , – [61]. . [3,7]. . , – . pylori. Helicobacter pylori | ||||||||||||||||||||||
| , % | ||
| ( ) II ( ) ( II) – | 70-90 20-70 10-20 5-10 5 |
, , . pylori 4-9 , [18,23,31,39]; 80% . pilori- [4]. 1994 . (IARC) H. pylori I , [34, 56].
, ; . pylori , , [8]. , , . pylori, ( – – CDH1 16q22.1) [10]. P. Lauren (1965 .), 3 – ( ), , . , . pylori- .
, 50-70- , .. . pylori. , – , – [10]. , . pylori, , , – , ; , , , , .
1988 . . rr [21], H. pylori. H. pylori [23,25] . (. 3). , H. pylori , . , , . pylori . , . pylori in vitro , [17], . , . pylori , . . pylori , , , .
. 3. ( . rr, 1988, 1990) [21,25]. 1 – 3 – ,
, , . pylori, , , [21,35,50].
– 26 132 [8].
: . pylori ( , MALT-), [12-14,19,28,46,57], (1-2%) H. pilory- [1,2], ( , ) .
, . pylori, – , , , . , , , – (). , . pylori [2]. , , 1% , ; 1% (“” “” P. Sipponen). , . pylori-accopo . , . pylori , () , , , . , , , – [12].
H. pylori- , . ( ) . [10].
, – , , , , , . , -, , , , – [8]. , Cag-A- . pylori . , , “” , . IL-8 Cag– . pylori, , [10] (. 4).
. 4. . . pylori,
, , . , IL-8 . , , IL-10, . , IL-10 , . pylori . : IL-10, , , . IL-10, , . pylori .
, , (HLA, IL-10) [15,41,62], – , , [2].
, . () .
– (. 5). ( , ), – . , , , ” – ” ” – ” [7]. , , , [3,44] (. . 5).
. 5.
– , , – . , , – – [7].
, , (. 2). . , . , 3 :
I – ( , );
II – ( );
III – ( ).
2.
| (I) | (II, III) | |||
| (IA) | (IB) | (IIB) | (III) | |
| + – – + + + | + – – + – – | + + – – – | + + – – – | |
, . , , , . , . , . , . , 53, , , . , – [3].
(98%) , – 38% [52], , . , , [55]. [3]. , , .
?
. pylori, , , , . .
. pylori , 1-3 – [33], , , [9].
, . pylori [51]. , [30,33,36,39].
. pylori- [33,38,58], [24,53]. , – [24,58]. – , 587 . pylori , , , 45 , , , . , [40].
. 6, . – . . . pylori .
. 6.
, . pylori, . . pylori, II [42]. ( ) – , ( , , ). : () , 2000 / 1000 / 7 . ( . pylori 4-6 ) : 480 /, 2000 /, 1000 / 7 .
17-18 2005 . III . pylori. – . , , ( 10 40 ). . pylori , 1500 /. , , 2000 / (2000 /) (400 /). 14 . , – . pylori . , . pylori, , , III .
, , . – , , .
, . , , , , . pylori ( ). , , , . ( 10 ), ( 20 ). : 30 50%.
, , , , , . , , . , 0,5 , – 0,07 [43]. , .
[16,45,47,60]. . Baisley ., >4 (10 /) (20 /) , [16]. 20 /, , , (38,5 19,4%), (52,8 42,5%) [60]. , [11,27].
, , . , -450: CYP2C19 CYP3A4. , , -450 [54]. , CYP2C19, , , . 63 , , , [37]. (10, 20 40 /) [20].
- .. Helicobacter pylori: // . . . – 2004. – 1. – C. 36-41.
- .. 100 Helicobacter pylori . ? // . . . – 2004. – 1 ( .). – . 12-18.
- .., .., .. . – .: -. 1998. – . 80-85, 272.
- .., .. // . . ., ., . -2002. – . 12, 3. – C. 7-14.
- .., .., .. . // . – 1999. – 1. – . 13-17.
- .., .. . – : -. 2003. – 412 .
- .., .., .., .. : , // . . . – 2004. – 1 ( .). – . 114-125.
- .., .. // Consilium medicum. – 2002. – . “”. – . 13-18.
- .., .. . pylori- // . . . – 2004. – 1 ( .). – . 153-159.
- .., .. , Helicobacter pylori, // . . – 2004. – . – . 57-60.
- Adachi ., Hashimoto ., Hanimnoto N. et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole // J.Gastroenterol. Hepatol. – 2003. – Vol. 18, 12. – P. 1392-1398.
- Alsolaiman M.M., Bakis G., Nazeer T. et. al. Five years of complete feraission of gastric diffuse large cell lymphoma after eradication of Helicobacter pylori infection // Gut. – 2003. – Vol. 52. – P. 507-509.
- Annibale ., Di Giulio E., Caruana P. et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 1723-1731.
- Asaka M., Kato M., Kudo M. et al. Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population // Eur. J. Gastroentrol. Hepatol. – 1995. – Vol. 7 (suppl.). – P. 7-10.
- zuma ., Ito S., Sato F. et al. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma, induced by Helicobacter pylori infection // Cancer. – 1998. – Vol. 82. – P. 1013-1018.
- Baisley K., Tejura ., Morocutti A. et al. Rabiprazole 10 mg is equivalent to esomeprazole 20 mg in control of gastric pH in healthy volunteers // Am. J. Gastroenterol. – 2001, – Vol. 96 (suppl.). – P. 148.
- Bode C. Vergani G. Helicobacter pylori stimulates, proliferation of Morris hepatoma (MH 1 Cl 7795) cells // Acta Gastroenterol. Belg. – 1993. – Vol. 56. – P. 69.
- Camargo M.C. Yepez M.C., Ceron . et al. Age at acquisition of Helicobacter pylori infection: Comparison of two areas with contrasting risk of gastric cancer // Helicobacter. – 2004. – Vol. 9. – P. 262-270.
- Caruso M.L., Fucci L. Histological identification of Helicobacter pylori in early and advanced gastric cancer // J. Clio. Gastroenterol. – 1990.- Vol. 2. – P. 601-602.
- Cloud M.L., Enas N., Humphries T.J., Bassion S. and the Rabeprazole Study Group. Results of three placebo-controlled dose-response clinical trails in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease // Dig. Dis. Sci. – 1998. – Vol.43. -P. 99-1000.
- Correa P. A human model of gastric carcinogenesis // Cancer Res. – 1998. – Vol. 48. – P. 3554-3560.
- Correa P. Helicobacter pylori and gastric cancer: state of the art // Cancer Epidemiol. Biomarkers Prew. – 1996. – Vol. 5. – P. 477-481.
- Correa P. The biological model of gastric carcinogenesis // JARC Sci. Publ. – 2004. – Vol. 157. – P. 301-310.
- Correa P., Fontham E.T.H., Bravo J. et al. Chemoprevention of gastric dysplasia: randomised trail of antioxidant supplements and anti-Helicobacter pylori therapy // J. Natl. Cancer Inst. – 2000. – Vol. 92. – P. 1881-1888.
- Correa P., Haenszel W., Cuetlo C. et al. Gastric, precancerous process in a high-risk, population: cohort follow-up // Cancer Res. – 1990. – Vol. 50. – P. 4737-4740.
- Danesh J. Helicobacter pylori infection and gastric cancer; systematic review of the epidemiological studies // Aliment Pharmacol. Ther. – 1999. – Vol. 13. – P. 851-856.
- Dekkers C.P.M., Better J.A., Thiodleifsson B. et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in treatment of active duodenal ulcer; a European multicentre study // Aliment Pharmacol. Ther. – 1999. – Vol. 13. – P. 179-186.
- Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of gastritis, Houston 1994 // Am. J. Surg. Pathol. – 1996. – Vol. 20. – P. 1161-1181
- Eidt S., Stolte M. Prevalence of intestinal metaplasia in Helicobacter pylori gastritis // Scand. J. Gastroenterol. – 1991. – Vol. 29. – P. 607-610.
- Fichman S., Niv Y. Histological changes in the gastric mucosa after Helicobacter pylori eradication // Eur. J. Gastroenterol. Hepatol. – 2004. – Vol. 16. 11. – P. 1183-1188.
- Forman D. Newell D.G., Fullerton F. et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation // BMJ. – 1991, – Vol. 302. – P. 1302-1305.
- Genla R.M. Can atrophic gastritis be diagnosed in the presence of Helicobacter pylori, infection? // Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000 // Eds. R.H. Hunt, G.N.J. Tytgat. – Dordrecht, Boston, London: Kluwer Academic Publishers, 2000. – P. 229-237.
- Hojo M., Miwa H., Ohkusa T. et. al. Alteration of histological gastritis after cure of Helicobacter pylori infection // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 1923-1932.
- International Agency for Research on Cancer. Anonymous live flukes and Helicobacter pylori. IARC Working Group oh the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC Monogr Eval Caciriog Risks Hum. 1994. – Vol. 61. – P. 1-241.
- Israel D.A., Peek R.M. Pathogenesis of Helicobacter pylori-induced gastric inflammation // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 1271-1290.
- Ito M., Haruma K., Kamada T. et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis // Aliment. Pharmacol. Ther. – 2002, – Vol. 16. – P. 1449-1456.
- Johnson D., Riff R., Perdomo C. et al. Rabeprazole: safety profile of a new proton piimp inhibitor // Gastroenterology – 1999. – Vol. 16. – P. 209.
- Kim N., Lim S.H., Lee K.H. et al. Long-term effects of Helicobacter pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers // Dig. Dis. Sci. – 2000. – Vol . 45. – P. 1754-1762.
- Kokkola A., Sipponen P., Pautelin. H. et al. The effect of Helicobacter pylore eradication on the natural course of atrophic gastritis with dysplasia // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 515-520.
- Leung W.K., Lin S.R., Clung J.Y. et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication // Gut. – 2004. – Vol. 53. 9. – P. 1244-1249.
- Machado J.C., Figueiredo C., Canedo P. Proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric adenocarcinoma // Gastroenterology. – 2003. – Vol. 125. – P. 364-371.
- Malfertheiner P., Megmud F., 0’Morain C, et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht 22000 consensus report // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 167-180.
- Morii M., Takata H., Fujisaki H., Takeguchi N. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric +, +-Pase is in correlation with the rate of acid activation of the inhibitor // Biochem. Pharmacol – 1990, – Vol. 39. – P. 661-667.
- Niwa ., Ikehara Y. Nakanishi H. et al. Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation // J. Histochem. Cytochem. – 2005. – Vol. 53. 1. – P. 75-85.
- Ohning G.V., Walsh J.H., Pisegna J.R, et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects // Aliment. Pharmacol. Thcr. – 2003, – Vol. 17. 9. – P. 1109-1114.
- Ozasa K., Kurata J.H., Higashi A. et al. Helicobacter pylori infection and atrophic gastritis: A nested case-control study in a rural town in Japan // Dig. Dis. Sch – 1999. – Vol. 44. – P. 253-256.
- Pantoflickova D., Dorta G., Ravic M. et al. Acid inhibition on the first day of dosing; comparison of four proton pump inhibitors // Aliment. Pharmacol. Ther. – 2003. – Vol. 17. 12. – P. 1507-1514.
- Peek R.M. Jr., Moss S.F., Tham K.T. et al. Helicobacter pylori CagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis // J. Natl. Cancer Inst. – 1997. Vol. 89. 42. – P. 863-868.
- Preston-Martin S,. Pike M.C., Ross U.K. et al. Increased cell division as a cause of human cancer // Cancer Res. – 1990. – Vol. 50. – P. 7415-7421.
- Rozen P. Cancer of the gastrointestinal tract: Early detection or early prevention? // Eur. J. Cancer Prev. – 2004. – Vol. 13. – P. 71-75.
- Sakaki N., Kozswa H., Egaea N. et al. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 198-203.
- Salva S., Filipe M. Intestinal metaplasia and its variants // Hum. Pathol. – 1986. – Vol. 17. – P. 988-995.
- Satoh K. Does eradication of Helicobacter pylori reverse atrophic gastritis and intestinal metaplasia? Data from Japan // Gastroenterol. Clin. North Am. – 2000. – Vol. 29. – P. 829-835.
- Shirai N., Furuta ., Miriyama Y. et al. Effects of CYP2C19 genotypic differences in the methabolism of omeprazole on intragastral pH // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 1929-1937.
- Stemmermann G.N. Intestinal metaplasia of the stomach. A status report // Cancer. – 1994. – Vol. 74. – P. 556-564.
- Testino G. Gastric preneoplastic changes // Recenti. Prog. Med. – 2004. – Vol. 95. – P. 239-244.
- Uemura N. The trend of the research on H. pylori eradication and gastric cancer prevention // Nippon. Rinsho. – 2004. – Vol. 62. – P. 571-576.
- Walker M.M. Is intestinal metaplasia of the stomach reversible? // Gut. – 2003. – Vol. 52. – P. 1-4.
- Warren J.R., Marshall B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis // Lancet. – 1983. – Vol. 1. – P. 1273-1275.
- Warrington S.J. et al. Rabeprazole is more potent than esomeprazole in control of gastric pH in healthy volunteers // Gut. – 2001. – Vol. 49 (suppl. 3). – P. 2800.
- Wright N.A. Mechanisms involved in gastric atrophy // Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000 // Eds. R.H. Hunts G. NJ. Tytgat. – Dordrecht, Boston, London: Kluwer Academic Publishers. – 2000. – P. 239-247.
- Wu M.S., Wu S.Y., Chen .J. et al. Interleukin-10 genotypes associate with, the risk of gastric carcinoma in Taiwanese // Intent. J. Cancer. – 2003, – Vol. 104. – P. 617-623.
- Xia H.H., Talley N.J. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implication in gastric carcinogenesis // Am. J. Gastroenterol. – 2001. – Vol. 96, 1. – P. 16-26.
: .
.. , .. , .. .
– , , .
, , . 2006, 4, . 38-48.
“”
. : ” “, ” -“,
” “, ” ” .
Источник
| |||||||||||||||||||||||
Источник